Skip to main content

Age Restriction Update for Beremagene Geperpavec-Svdt (Vyjuvek) Procedure Code J3401

Last updated on

Effective for dates of service on or after March 1, 2026, the Food and Drug Administration (FDA) has approved an age expansion for beremagene geperpavec-svdt (Vyjuvek) procedure code J3401 to include adult and pediatric clients of all ages.

For more information, call the TMHP Contact Center at 800-925-9126.

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in their MCO. Administrative procedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the member’s specific MCO for details.